United Therapeutics Corporation $UTHR Shares Bought by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 133.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,355 shares of the biotechnology company’s stock after buying an additional 1,347 shares during the period. Kestra Private Wealth Services LLC’s holdings in United Therapeutics were worth $1,147,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. WealthCollab LLC increased its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB increased its stake in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $44,000. Finally, Geneos Wealth Management Inc. increased its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $470.95, for a total value of $10,596,375.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 469,205 shares of company stock worth $253,860,521 over the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $570.40 on Friday. The stock has a market cap of $25.00 billion, a P/E ratio of 20.44, a P/E/G ratio of 1.62 and a beta of 0.60. The stock’s 50 day simple moving average is $543.83 and its 200-day simple moving average is $497.82. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the previous year, the company earned $6.19 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on UTHR. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Morgan Stanley boosted their target price on United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Wells Fargo & Company boosted their target price on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 31st. Finally, HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $601.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.